AU2002322066A1 - N-terminally truncated galectin-3 and antibodies for treating cancer - Google Patents
N-terminally truncated galectin-3 and antibodies for treating cancerInfo
- Publication number
- AU2002322066A1 AU2002322066A1 AU2002322066A AU2002322066A AU2002322066A1 AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1 AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- treating cancer
- terminally truncated
- truncated galectin
- galectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000000802 Galectin 3 Human genes 0.000 title 1
- 108010001517 Galectin 3 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29697001P | 2001-06-08 | 2001-06-08 | |
| US60/296,970 | 2001-06-08 | ||
| PCT/US2002/018478 WO2002100343A2 (en) | 2001-06-08 | 2002-06-10 | N-terminally truncated galectin-3 and antibodies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002322066A1 true AU2002322066A1 (en) | 2002-12-23 |
Family
ID=23144316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002322066A Abandoned AU2002322066A1 (en) | 2001-06-08 | 2002-06-10 | N-terminally truncated galectin-3 and antibodies for treating cancer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1534317A4 (en) |
| AU (1) | AU2002322066A1 (en) |
| CA (1) | CA2488850A1 (en) |
| WO (1) | WO2002100343A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| KR101025143B1 (en) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | Hydrolytically Stable Maleimide-terminated Polymers |
| AU2004229399B2 (en) | 2003-04-07 | 2010-08-05 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
| CA2742265C (en) * | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| CN102488619B (en) | 2011-12-05 | 2014-08-06 | 上海交通大学 | Device for continuously producing exenatide microspheres and method for controlling release rate of microspheres |
| JP2016507503A (en) | 2012-12-20 | 2016-03-10 | ヘンリー フォード ヘルス システム | Method for treating diastolic heart failure by inhibiting galectin-3 |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| US20150157691A1 (en) * | 2013-12-05 | 2015-06-11 | Texas Tech University System | Galectin-3 to Treat Ovarian Cancer |
| US20150216931A1 (en) * | 2014-02-03 | 2015-08-06 | Texas Tech University System | Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitors |
| EP3188716B1 (en) | 2014-09-03 | 2022-10-26 | GeneSegues, Inc. | Therapeutic nanoparticles and related compositions, methods and systems |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0218700A4 (en) * | 1985-04-23 | 1988-09-19 | Medical Biology Inst | DETERMINATION OF AN IGE BINDING PROTEIN BY MOLECULAR CLONING. |
| US20020019009A1 (en) * | 1999-12-09 | 2002-02-14 | Roggen Erwin Ludo | High throughput screening (HTS) assays |
| AU2001243622A1 (en) * | 2000-03-13 | 2001-09-24 | La Jolla Institute For Allergy And Immunology | Monocyte chemoattractant activity of galectin-3 |
-
2002
- 2002-06-10 CA CA002488850A patent/CA2488850A1/en not_active Abandoned
- 2002-06-10 AU AU2002322066A patent/AU2002322066A1/en not_active Abandoned
- 2002-06-10 EP EP02756157A patent/EP1534317A4/en not_active Withdrawn
- 2002-06-10 WO PCT/US2002/018478 patent/WO2002100343A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2488850A1 (en) | 2002-12-19 |
| EP1534317A4 (en) | 2005-10-12 |
| EP1534317A2 (en) | 2005-06-01 |
| WO2002100343A2 (en) | 2002-12-19 |
| WO2002100343A3 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AUPR395801A0 (en) | Antibodies against cancer | |
| AU2002338015A1 (en) | Human CDR-grafted antibodies and antibody fragments thereof | |
| IL200404A (en) | Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer | |
| AU2003224076A1 (en) | Antibody combination useful for tumor therapy | |
| AU2002305478A1 (en) | Conjugates of reduced antibodies and biomolecules | |
| AU2002364708A1 (en) | Novel compositions and methods for cancer | |
| AU2001290860A1 (en) | Spas-1 cancer antigen | |
| AU2002349543A1 (en) | Tumor antigens | |
| AU2002351374A1 (en) | Antibodies to treat cancer | |
| AU2002322066A1 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
| AU2002315066A1 (en) | Methods for making antibody fragments and compositions resulting therefrom | |
| AU2002308642A1 (en) | Methods for treating cancer | |
| AU2001257325A1 (en) | Cancer treatment | |
| AU2002337943A1 (en) | Novel compositions and methods for cancer | |
| AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer | |
| AU2002360815A1 (en) | Human breast cancer biomarkers | |
| AU2002305138A1 (en) | Methods and materials for cancer treatment | |
| AU5632500A (en) | Cancer associated antigens and uses therefor | |
| AU2002363807A1 (en) | Breast cancer associated polypeptide | |
| AU2002366364A1 (en) | E2f and cancer therapy | |
| AU2002351382A1 (en) | Combination cancer therapy | |
| AU2002360454A1 (en) | Methods and compositions for treating cancer | |
| AU2001257168A1 (en) | Cancer treatment | |
| AUPR589001A0 (en) | An antibody cancer therapeutic | |
| AU2002356097A1 (en) | Hydrazinopeptoids and their uses for treating cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |